Matinas BioPharma Holdings, Inc. Receives NYSE American Delisting Notice

Matinas BioPharma Holdings, Inc. faces a critical compliance failure, receiving a formal notice from the NYSE American LLC that it is no longer in compliance with the exchange's continued listing standards. The 8-K filing, submitted on April 3, 2026, signals immediate and severe pressure on the company's public market standing, triggering mandatory disclosure requirements under SEC regulations.

The specific listing rule or standard the company failed to satisfy is not detailed in the initial filing, but such notices typically stem from falling below minimum thresholds for share price, market capitalization, or stockholders' equity. The filing includes Item 3.01, which mandates disclosure of a delisting notice or a failure to meet a continued listing rule, and Item 9.01 for related financial statements and exhibits. This procedural step initiates a potential review or appeal period, during which Matinas BioPharma must present a plan to regain compliance or face the transfer of its listing to an over-the-counter market.

The delisting notice places the biopharmaceutical firm under intense financial and operational scrutiny. Failure to rectify the situation risks severe consequences, including diminished liquidity, reduced institutional investor access, and a significant blow to corporate credibility. This development marks a pivotal moment for the company, forcing management to address underlying financial weaknesses or strategic missteps to preserve its listed status and shareholder value.